BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 30, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/27 cls
Gilead Sciences Inc. (NASDAQ:GILD) RBC Capital Markets Michael Yee Price target Market outperform 3% $48.72
Yee raised his target to $56 from $48 after identifying areas of potential tax savings from the company's acquisition of Pharmasset Inc. that other analysts may not account for in their models. He thinks Gilead could domicile Pharmasset's PSI-7977 IP in Ireland, where it has a subsidiary, reducing tax liability on sales of the product to about 15% vs. 25-30% tax rates in other analyst models. PSI-7977, a single isomer form of PSI-7851, a nucleotide analog HCV NS5B polymerase inhibitor, is in Phase III testing to treat HCV.
Illumina Inc. (NASDAQ:ILMN) Wedbush

Read the full 770 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >